Xenetic Biosciences, Inc.
Symbol: XBIO (NASDAQ)
3.27
▼ (-0.75%) -0.025
Company Description:
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
Key Stats
- Today's Open: $3.265
- Today's High: $3.265
- Today's Low: $3.265
- Today's Volume: 207
- Yesterday Close: $3.2896
- Yesterday High: $3.29
- Yesterday Low: $3.08
- Yesterday Volume: 56.38K
- Last Min Volume: 105
- Last Min High: $3.265
- Last Min Low: $3.265
- Last Min VWAP: $3.265
Company Profile
- Name: Xenetic Biosciences, Inc.
- Website: https://www.xeneticbio.com
- Listed Date: 2012-05-16
- Location: FRAMINGHAM, MA
- Market Status: Active
- CIK Number: 0001534525
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $5.07M
- Round Lot: 100
- Outstanding Shares: 1.54M
- Asset Type: CS
RECENT FILINGS FOR XBIO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-13 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 10-K/A | View |
| 2025-04-29 | 10-K/A | View |
| 2025-04-10 | 8-K | View |
| 2025-03-19 | 8-K/A | View |
| 2025-03-19 | 8-K | View |
| 2025-03-18 | 10-K | View |
| 2024-12-13 | 4 | View |
| 2024-12-13 | 4 | View |
| 2024-12-13 | 4 | View |
| 2024-12-13 | 4 | View |
| 2024-12-13 | 8-K | View |
| 2024-11-13 | 8-K | View |
| 2024-11-12 | 10-Q | View |
| 2024-11-07 | 8-K | View |
| 2024-11-01 | EFFECT | View |
| 2024-10-31 | 8-K | View |
Latest News on XBIO